The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
ASH 2018 | MSC-FFM for the treatment of pediatric and adult patients with steroid-refractory graft-versus-host disease
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells that showed promising activity for the treatment of steroid-resistant acute graft-versus-host disease (SR aGvHD). MSCs modulate immune responses by secreting soluble factors that can modify the stimulation, proliferation and maturation of T- and B-lymphocytes, natural killer cells, and dendritic cells. Furthermore, MSCs also induce the differentiation of regulatory T cells and regulate the Th1/Th2 ratio. At present, there are several ongoing randomized trials investigating the impact of MSCs on GvHD prevention or treatment.
At the 60th American Society of Hematology Annual Meeting & Exposition, Peter Bader from Hospital for Children and Adolescents; Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Frankfurt, Germany, presented treatment data of pediatric and adult patients with either SR GvHD (27%) or GvHD treated with MSC-Frankfurt am Main (MSC-FFM), a novel MSC manufacturing protocol characterized by high in vitro potency and near-identity of individual doses developed by Professor Bader and colleagues.
Patients and methods
- N = 61 pediatric patients
- Median age = 7.7 years (range, 0.5–0)
- N = 31 adult patients
- Median age = 42.4 years (range, 18.4–65.6)
- Patients from 23 centers in 6 countries were included in this study
- Severe GvHD: 37% grade III, 59% grade IV
- Donors: MSD (n = 21, 23%), MUD (n = 56, 61%), haploidentical ( n= 14, 15%), and MMUD (n = 1, 1%)
- Myeloablative conditioning with TBI-(treosulfan, busulfan and fludarabine) based regimen
- 89% of patients had received immunosuppression for GvHD prophylaxis
- Recommended dose: 4 weekly doses of 1-2M MSC/kg
- Patients received 3 doses on average
Key findings
- Response 28 days after MSC:
- CR: 28%
- PR: 54%
- NR: 15%
- Response at last follow-up:
- CR: 51%
- PR: 30%
- NR: 17%
- Day-28 response rates were highly predictive of long-term responsiveness
- Six patients relapsed and died
- Twenty-eight deaths were treatment-related
- 6-month overall survival for children and adults: 68% and 54%, respectively
- Adverse events: headache, nausea/vomiting were reported shortly after infusion
Professor Bader concluded that MSC-FFM is effective for the treatment of severe pediatric and adult advanced GvHD. “The very low relapse mortality may suggest that severe GvHD effectively suppresses leukemic recurrence.” A randomized trial for the treatment of SR aGvHD is planned to start in 2019.
References